ANI Pharmaceuticals Q3 revenue beats estimates on Cortrophin Gel growth
ANIP•ANI Pharmaceuticals’ third-quarter revenue rose 27.6% to $290.78 million, beating the $280.20 million consensus estimate, with growth from Cortrophin Gel. The company narrowed its 2026 revenue outlook to $1.085 billion-$1.125 billion, lowered its Cortrophin Gel forecast and raised its adjusted EPS forecast.
1. Quarterly results
Third-quarter revenue was $290.78 million, up 27.6% and above the $280.20 million analyst consensus. Adjusted EPS was $2.70, net income was $35.10 million and adjusted EBITDA was $83.30 million.
2. 2026 outlook
ANI narrowed its 2026 revenue guidance to $1.085 billion-$1.125 billion and lowered its Cortrophin Gel revenue outlook to $480 million-$500 million. It raised its adjusted non-GAAP EPS forecast to $9.37-$9.71.
3. Growth drivers and offer
The company said Cortrophin Gel revenue rose on momentum from gout expansion and progress in specialty areas, while specialty pharmacy network capacity constraints slowed revenue conversion. Generics revenue increased on demand for existing products and new launches. ANI also announced an offer to acquire Egetis Therapeutics to expand its rare disease portfolio.
